Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. AKBA
stocks logo

AKBA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
56.18M
+20.82%
-0.015
-85%
59.33M
+3.47%
0.002
-102%
Estimates Revision
The market is revising No Change the revenue expectations for Akebia Therapeutics, Inc. (AKBA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -46.28%.
Revenue Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
EPS Estimates for FY2025
No Change
down Image
0.00%
In Past 3 Month
Stock Price
Go Down
down Image
-46.28%
In Past 3 Month
Wall Street analysts forecast AKBA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKBA is 6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast AKBA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKBA is 6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.590
sliders
Low
5.00
Averages
6.00
High
7.00
Current: 1.590
sliders
Low
5.00
Averages
6.00
High
7.00
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$8 -> $6
2025-10-30
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$8 -> $6
2025-10-30
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on Akebia to $6 from $8 and keeps a Buy rating on the shares. The firm cites the announcement of the company not pursuing initiation of the Phase 3 VALOR trial or associated broad chronic kidney disease non-dialysis labeling for Vafeso for the target drop.
H.C. Wainwright
Matthew Caufield
initiated
$8
2025-06-04
Reason
H.C. Wainwright
Matthew Caufield
Price Target
$8
2025-06-04
initiated
Reason
H.C. Wainwright analyst Matthew Caufield assumed coverage of Akebia with a Buy rating and $8 price target. The company's approved product Vafseo indicated for the treatment of anemia due to chronic kidney disease in adults receiving dialysis for at least three months, continues to gain uptake among dialysis organizations, the analyst tells investors in a research note. The firm believes the ongoing Vafseo launch can offset generic impact on the company's other approved product Auryxia, which has focused commercially on the hyperphosphatemia indication.
HC Wainwright & Co.
Ed Arce
Strong Buy
Reiterates
$7.5
2025-04-04
Reason
HC Wainwright & Co.
Ed Arce
Price Target
$7.5
2025-04-04
Reiterates
Strong Buy
Reason
Jefferies
Roger Song
Strong Buy
Initiates
$6
2025-04-01
Reason
Jefferies
Roger Song
Price Target
$6
2025-04-01
Initiates
Strong Buy
Reason
Jefferies initiated coverage of Akebia with a Buy rating and $6 price target. Akebia is a commercial-stage biotech specializing in kidney disease, the analyst tells investors in a research note. The company's initial U.S. launch of Vafseo under the Transitional Drug Add-on Payment Adjustment is looking encouraging with potential durable sales post the TDAPA, the analyst tells investors in a research note. Jefferies says the company has a few early pipeline products with upside potential.
HC Wainwright & Co.
Ed Arce
Strong Buy
Reiterates
$7.5
2025-03-14
Reason
HC Wainwright & Co.
Ed Arce
Price Target
$7.5
2025-03-14
Reiterates
Strong Buy
Reason
Piper Sandler
Allison Bratzel
Buy
Maintains
$4 → $6
2025-03-14
Reason
Piper Sandler
Allison Bratzel
Price Target
$4 → $6
2025-03-14
Maintains
Buy
Reason
Piper Sandler raised the firm's price target on Akebia to $6 from $4 and keeps an Overweight rating on the shares. The firm says it remains a buyer of Akebia shares following Q4 reporting, which included a look at Vafseo launch progress that Piper finds encouraging. The firm thinks the stock reaction is misplaced given its view that the Vafseo launch is poised to exceed expectations, with Q1 2025 revenue expected to be $10M-$11M, essentially doubling consensus and PSC estimates.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Akebia Therapeutics Inc (AKBA.O) is 80.51, compared to its 5-year average forward P/E of -3.91. For a more detailed relative valuation and DCF analysis to assess Akebia Therapeutics Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-3.91
Current PE
80.51
Overvalued PE
20.55
Undervalued PE
-28.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.02
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.39
Undervalued EV/EBITDA
-2.44

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.75
Current PS
0.00
Overvalued PS
2.77
Undervalued PS
0.73
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders areSelling! The selling amount has increased 1879.81% over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders areSelling! The selling amount has increased 1879.81% over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

AKBA News & Events

Events Timeline

(ET)
2025-12-01
07:18:00
Q32 Bio (QTTB) Sells ADX-097 to Akebia Therapeutics for $12M
select
2025-12-01
07:17:00
Akebia Acquires Rare Kidney Drug AKB-097 for $7M
select
2025-11-10 (ET)
2025-11-10
07:07:30
Akebia Announces Q3 Earnings Per Share of 0 Cents Compared to (10 Cents) Last Year
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
8.5
12-01Benzinga
What’s Driving the Surge in Small-Cap Q32 Bio Stock This Monday?

  • Q32 Bio Stock Performance: Q32 Bio Inc. (NASDAQ: QTTB) saw a significant increase in stock price, rising 115.07% to $4.71, with a trading volume of 70.56 million shares compared to its average of 217.704 thousand.

  • Sale of ADX-097: The company sold its Phase 2 complement inhibitor, ADX-097, to Akebia Therapeutics Inc. (NASDAQ: AKBA) for $12 million upfront, with potential total payments reaching up to $592 million based on future milestones and royalties.

  • Details on ADX-097: ADX-097 is a humanized anti-C3d Factor H monoclonal antibody designed to inhibit complement activation, with applications in various diseases, including kidney and autoimmune conditions.

  • Future Plans for Q32 Bio: Q32 Bio retains rights to its tissue-targeted complement inhibitor platform and is exploring strategic options for its remaining assets, expecting to fund operations into the second half of 2027 with the proceeds from the ADX-097 sale.

[object Object]
Preview
7.5
12-01PRnewswire
Q32 Bio Sells ADX-097 for $12M, Extends Cash Runway into 2027
  • Cash Runway Extended: Q32 Bio's sale of its Phase 2 complement inhibitor ADX-097 to Akebia Therapeutics secures $12 million in upfront and near-term milestone payments, extending its cash runway into the second half of 2027, ensuring continued investment in advancing bempikibart for alopecia areata.
  • Significant Potential Earnings: The transaction allows Q32 Bio to potentially receive up to $592 million upon achieving specific development, regulatory, and commercial milestones, highlighting the product's market potential and future profitability.
  • Strategic Focus Maintained: Q32 Bio retains its wholly owned tissue-targeted complement inhibitor platform, including ADX-096 and other early-stage assets, while continuing to evaluate strategic options for these programs, ensuring ongoing innovation and development in its core technology area.
  • Strong Market Demand: With alopecia areata affecting approximately 700,000 individuals, Q32 Bio's bempikibart is poised to transform the treatment landscape, addressing the urgent need for effective therapies and further solidifying its market position in the biotechnology sector.
[object Object]
Preview
7.5
12-01Newsfilter
Akebia Acquires Q32 Bio's Next-Gen Kidney Disease Treatment
  • Acquisition of New Drug: Akebia acquired AKB-097 from Q32 Bio for $7 million, which is expected to be utilized in treating various rare kidney diseases, thereby enhancing its competitive position in the renal market.
  • Clinical Trial Initiation: Akebia plans to initiate a Phase 2 clinical trial for AKB-097 in 2026, with preliminary clinical data expected in 2027, further advancing its product development pipeline.
  • Multiple Indication Evaluation: As a targeted complement inhibitor, AKB-097 aims to address multiple complement-mediated rare kidney diseases, potentially significantly improving patient outcomes and filling a market gap.
  • Strategic Development: Akebia's CEO emphasized that establishing a kidney disease drug pipeline is central to the company's strategy, aiming to enhance the quality of life for kidney disease patients and drive long-term growth for the company.
Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Akebia Therapeutics Inc (AKBA) stock price today?

The current price of AKBA is 1.59 USD — it has increased 1.27 % in the last trading day.

arrow icon

What is Akebia Therapeutics Inc (AKBA)'s business?

Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company's portfolio includes Vafseo and Auryxia. Vafseo is an orally administered medicine, approved by the United States Food and Drug Administration (FDA), for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis for at least three months. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA) in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Its HIF-based product candidates and other pipeline assets are being evaluated to target areas of unmet needs. Its product candidates include AKB-9090, AKB-10108, AKB-097 and praliciguat.

arrow icon

What is the price predicton of AKBA Stock?

Wall Street analysts forecast AKBA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AKBA is 6.00 USD with a low forecast of 5.00 USD and a high forecast of 7.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Akebia Therapeutics Inc (AKBA)'s revenue for the last quarter?

Akebia Therapeutics Inc revenue for the last quarter amounts to 58.77M USD, increased 57.01 % YoY.

arrow icon

What is Akebia Therapeutics Inc (AKBA)'s earnings per share (EPS) for the last quarter?

Akebia Therapeutics Inc. EPS for the last quarter amounts to 0.00 USD, decreased -100.00 % YoY.

arrow icon

What changes have occurred in the market's expectations for Akebia Therapeutics Inc (AKBA)'s fundamentals?

The market is revising No Change the revenue expectations for Akebia Therapeutics, Inc. (AKBA) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -46.28%.
arrow icon

How many employees does Akebia Therapeutics Inc (AKBA). have?

Akebia Therapeutics Inc (AKBA) has 181 emplpoyees as of December 05 2025.

arrow icon

What is Akebia Therapeutics Inc (AKBA) market cap?

Today AKBA has the market capitalization of 421.93M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free